Efficacy of intranasal olopatidine hydrochloride as an add on therapy in mild to moderate allergic rhinitis

Authors

  • Sam Anbu Sahayam J. Department of Pharmacology, Government Kanyakumari Medical College, Asaripallam, Nagercoil, Tamil Nadu, India
  • Vasanthira K. Department of Pharmacology, Trichy SRM Medical College, Trichy, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20211025

Keywords:

Allergic rhinitis, Eosinophil count, Olopatidine hydrochloride, Saline drops

Abstract

Background: Treatment with intranasal olopatidine hydrochloride spray is proposed for patients with chronic perennial and seasonal rhinitis. Hence we compared the efficacy of intranasal mometasone furoate as an add-on therapy with existing standard treatment in a randomized, open label comparative study.

Methods: A prospective, randomized, single blinded, comparative study in patients with chronic perennial and seasonal rhinitis. Patients were divided into two groups to receive intranasal olopatidine therapy and intranasal saline plus existing standard treatment with levocetrizine and vitamin C orally. Improvement in symptoms like nasal obstruction, nasal discharge, sneezing, nasal itching, itching of eyes, watering of eyes were assessed by a questionnaire at 2, 4, 6 and 8 weeks and  by a reduction of  eosinophil count in blood and nasal smear examination  at baseline and 8 weeks.

Results: At the end of  8 weeks the percentage reduction of nasal obstruction in  olopatidine hydrochloride  and saline were  93.1%  and  36.07% respectively, rhinorrhoea was 90.34% and 36.42%, nasal itching  was 85.76% and 41.37%  sneezing symptoms were 89.6%  and 37.86%, itching in the eyes was 94.6% and 44.05% and watering in the eyes were 87.1% in group A and 38.07% in group B. At the end of 8 weeks, there was reduction in absolute eosinophil count and it attributed to 57.5% in olopatidine hydrochloride and 11.9% in saline group and reduction in nasal smear count scoring was 60.7% and 18.2% respectively.

Conclusions: Intranasal olopatidine hydrochloride is highly effective, in the treatment of allergic rhinitis.

Author Biography

Sam Anbu Sahayam J., Department of Pharmacology, Government Kanyakumari Medical College, Asaripallam, Nagercoil, Tamil Nadu, India

ASSISTANT PROFESSOR

DEPARTMENT OF PHARMACOLOGY

References

Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008. Allergy. 2008;63:8-160.

Salo PM, Calatroni A, Gergen PJ, Hoppin JA, Sever ML, Jaramillo R, et al. Allergy-related outcomes in relation to serum IgE: results from the National Health and Nutrition Examination Survey 2005-2006. J Allerg Clin Immunol. 2011;127(5):1226-35.

Barnes PJ, Pulmonary pharmacology. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman and Gilman’s, The Pharmacological Basis of Therapeutics. 12th edn. McGraw Hill Companies; 2011:922.

Maiti R, Jaida J, Rahman J, Gaddam R, Palani A. Olopatadine hydrochloride and rupatadine fumarate in seasonal allergic rhinitis: a comparative study of efficacy and safety. J Pharmacol Pharmacotherap. 2011;2(4):270.

Dykewicz MS, Wallace DV, Baroody F, Bernstein J, Craig T, Finegold I, et al. Treatment of seasonal allergic rhinitis: an evidence-based focused 2017 guideline update. Ann Allerg Asthma Immunol. 2017;119(6):489-511.

Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allerg Clin Immunol. 2001;108(1):S2-8.

Meltzer EO. Allergic rhinitis. Immunol Allerg Clin North Am. 2016;36(2):235-48.

May JR, Dolen WK. Management of allergic rhinitis: a review for the community pharmacist. Clin Therap. 2017;39(12):2410-9.

Leonardi A, Quintieri L. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Expert Opin Pharmacother. 2010;11(6):969-81.

Norman H. Nie, SPSS (Statistical Package for Social Sciences) version 17, 2020.

Ramakrishnan R, ICMR (Indian Council of Medical Research), Measurement of study variables. Available at: nie.gov.in. Accesssed on 20 January 2021.

Patel AK, Nagpal TP. Comparison of blood absolute eosinophil count and nasal smear eosinophils with symptoms and severity of clinical score in patients of allergic rhinitis. Indian J Allerg Asthma Immunol. 2014;28(2):74.

Pal I, Babu AS, Halder I, Kumar S. Nasal smear eosinophils and allergic rhinitis. Ear Nose Throat J. 2017;96(10-11):E17-22.

Gross GN, Berman G, Amar NJ, Caracta CF, Tantry SK. Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. Ann Allerg Asthma Immunol. 2019;122(6):630-8.

Shah J, Patel P. Evaluation of effectiveness of rupatadine and olopatadine in patients of allergic rhinitis at Indore: a randomized control trial. Int J Basic Clin Pharmacol. 2017;6:1753-7.

Bachert C. Persistent rhinitis- allergic or non allergic. Allergy. 2004;59:11-5.

Hansel FK. The cytology of the secretions in allergy. Clin Allerg. 1953:408-19.

Downloads

Published

2021-03-22

How to Cite

Sahayam J., S. A., & K., V. (2021). Efficacy of intranasal olopatidine hydrochloride as an add on therapy in mild to moderate allergic rhinitis. International Journal of Basic & Clinical Pharmacology, 10(4), 415–419. https://doi.org/10.18203/2319-2003.ijbcp20211025

Issue

Section

Original Research Articles